Hydroflumethiazide
FDA-approved product (tablet, oral), marketed as Diucardin, Hydroflumethiazide, Saluron.
- Registered studies
- 1
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Thiazides, plain; Thiazides, combinations with psycholeptics and/or analgesics
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Hydroflumethiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more47.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents47.8% AI-predicted activityagainst K. pneumoniae1 registered study
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive47.6% AI-predicted activityagainst K. pneumoniae5 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection47.3% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Ergoloid MesylatesExisting use: Cardiovascular disease47.1% AI-predicted activityagainst K. pneumoniae2 registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more47.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma47.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more46.7% AI-predicted activityagainst K. pneumoniae35 registered studies
- Hydrocodone BitartrateExisting use: Cough, Drug dependence, Pain46.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more46.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis46.1% AI-predicted activityagainst K. pneumoniae43 registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more46.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension
NCT01260857 · start 2013-03
Registered record
- Registry ID
- NCT01260857
- Conditions
- Hypertension
- Interventions
- Aldazide
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Withdrawn
- Start
- 2013-03
- Completion
- 2015-02
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionAldazidePhaseNot recordedRegistry statusWithdrawn